The Global Health Body Issues Concern Over Critical Shortage of Weight-Loss Jabs

Under 10% of people that would benefit from weight-loss injections such as Wegovy can access them, caution the WHO as it publishes its initial recommendations on the drugs.

Given in excess of 1,000,000,000 people worldwide now classified as obese, it is urging broader and more equitable access to this class of drugs.

Based on projections, over two billion could be obese by 2030 unless action is taken.

"The latest guidelines affirms that excess weight is a chronic disease that can be managed with holistic and lifelong support," remarked its chief Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and logistical bottlenecks are significant barriers to widespread availability to the jabs that can help people shift substantial body mass, explains the organization.

Skinny Jab Scarcity

Even in the current most favorable outlook, the production of such drugs would only suffice for about 100 million people – fewer than 10% of eligible patients, as stated by the WHO.

The guideline urges governments and firms to widen access, via approaches including licensing agreements.

The intellectual property rights on a key compound – the main ingredient of a leading brand – is set to lapse in multiple countries in 2026.

The Way Weight-Loss Jabs Work

GLP-1 drugs mimick a natural hormone to reduce digestion speed, curb appetite and boost feelings of fullness so people eat less.

People usually start to lose weight within a few weeks of starting on the regular doses.

Evidence indicates patients may see weight return after a year of stopping the drug, because their typical hunger return.

To be above a healthy weight raises your chance for experiencing medical conditions, including type 2 diabetes, heart disease, brain attack, and certain cancers.

Excess weight impacts individuals in all nations and was linked to millions of fatalities worldwide in 2024, as per the WHO.